Nuvalent (NUVL)
(Delayed Data from NSDQ)
$84.96 USD
+0.38 (0.45%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $85.00 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.96 USD
+0.38 (0.45%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $85.00 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Why Earnings Season Could Be Great for Nuvalent (NUVL)
by Zacks Equity Research
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
by Zacks Equity Research
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
by Zacks Equity Research
Here is how DICE Therapeutics, Inc. (DICE) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going
by Zacks Equity Research
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.